Obesity - Pipeline Review - H1 2014





Published: March 2014 | Pages: 562 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘Obesity - Pipeline Review, H1 2014’, provides an overview of the Obesity’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  The report provides a snapshot of the global therapeutic landscape of Obesity 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 

 Reasons to buy 

 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for Obesity 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Introduction 8 

 Obesity Overview 9 

 Therapeutics Development 10 

 Obesity - Therapeutics under Development by Companies 12 

 Obesity - Therapeutics under Investigation by Universities/Institutes 22 

 Obesity - Pipeline Products Glance 26 

 Obesity - Products under Development by Companies 30 

 Obesity - Products under Investigation by Universities/Institutes 42 

 Obesity - Companies Involved in Therapeutics Development 45 

 Obesity - Therapeutics Assessment 151 

 Drug Profiles 178 

 Obesity - Recent Pipeline Updates 452 

 Obesity - Dormant Projects 510 

 Obesity - Discontinued Products 522 

 Obesity - Product Development Milestones 528 

 Appendix 536 

  

 List of Tables 

 Number of Products under Development for Obesity, H1 2014 35 

 Number of Products under Development for Obesity - Comparative Analysis, H1 2014 36 

 Number of Products under Development by Companies, H1 2014 38 

 Number of Products under Development by Companies, H1 2014 (Contd..1) 39 

 Number of Products under Development by Companies, H1 2014 (Contd..2) 40 

 Number of Products under Development by Companies, H1 2014 (Contd..3) 41 

 Number of Products under Development by Companies, H1 2014 (Contd..4) 42 

 Number of Products under Development by Companies, H1 2014 (Contd..5) 43 

 Number of Products under Development by Companies, H1 2014 (Contd..6) 44 

 Number of Products under Development by Companies, H1 2014 (Contd..7) 45 

 Number of Products under Development by Companies, H1 2014 (Contd..8) 46 

 Number of Products under Investigation by Universities/Institutes, H1 2014 48 

 Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 49 

 Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 50 

 Comparative Analysis by Late Stage Development, H1 2014 51 

 Comparative Analysis by Clinical Stage Development, H1 2014 52 

 Comparative Analysis by Early Stage Development, H1 2014 53 

 Comparative Analysis by Unknown Stage Development, H1 2014 54 

 Products under Development by Companies, H1 2014 55 

 Products under Development by Companies, H1 2014 (Contd..1) 56 

 Products under Development by Companies, H1 2014 (Contd..2) 57 

 Products under Development by Companies, H1 2014 (Contd..3) 58 

 Products under Development by Companies, H1 2014 (Contd..4) 59 

 Products under Development by Companies, H1 2014 (Contd..5) 60 

 Products under Development by Companies, H1 2014 (Contd..6) 61 

 Products under Development by Companies, H1 2014 (Contd..7) 62 

 Products under Development by Companies, H1 2014 (Contd..8) 63 

 Products under Development by Companies, H1 2014 (Contd..9) 64 

 Products under Development by Companies, H1 2014 (Contd..10) 65 

 Products under Development by Companies, H1 2014 (Contd..11) 66 

 Products under Investigation by Universities/Institutes, H1 2014 67 

 Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 68 

 Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 69 

 Obesity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 70 

 Obesity - Pipeline by Shionogi & Co., Ltd., H1 2014 71 

 Obesity - Pipeline by Amgen Inc., H1 2014 72 

 Obesity - Pipeline by Sanofi, H1 2014 73 

 Obesity - Pipeline by AstraZeneca PLC, H1 2014 74 

 Obesity - Pipeline by Eli Lilly and Company, H1 2014 75 

 Obesity - Pipeline by Athersys, Inc., H1 2014 76 

 Obesity - Pipeline by GlaxoSmithKline plc, H1 2014 77 

 Obesity - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 78 

 Obesity - Pipeline by Merck & Co., Inc., H1 2014 79 

 Obesity - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 80 

 Obesity - Pipeline by Euroscreen S.A., H1 2014 81 

 Obesity - Pipeline by Novo Nordisk A/S, H1 2014 82 

 Obesity - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 83 

 Obesity - Pipeline by Plexxikon Inc., H1 2014 84 

 Obesity - Pipeline by Ipsen S.A., H1 2014 85 

 Obesity - Pipeline by CARDIONOVA LTD., H1 2014 86 

 Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2014 87 

 Obesity - Pipeline by GTx, Inc., H1 2014 88 

 Obesity - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 89 

 Obesity - Pipeline by LEO Pharma A/S, H1 2014 90 

 Obesity - Pipeline by Pfizer Inc., H1 2014 91 

 Obesity - Pipeline by Vivus, Inc., H1 2014 92 

 Obesity - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 93 

 Obesity - Pipeline by OPKO Health, Inc., H1 2014 94 

 Obesity - Pipeline by Genfit SA, H1 2014 95 

 Obesity - Pipeline by Arrowhead Research Corporation, H1 2014 96 

 Obesity - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 97 

 Obesity - Pipeline by Calzada Limited, H1 2014 98 

 Obesity - Pipeline by NeuroSearch A/S, H1 2014 99 

 Obesity - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014 100 

 Obesity - Pipeline by Arena Pharmaceuticals, Inc., H1 2014 101 

 Obesity - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2014 102 

 Obesity - Pipeline by Handok Inc., H1 2014 103 

 Obesity - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2014 104 

 Obesity - Pipeline by LG Life Sciences, Ltd., H1 2014 105 

 Obesity - Pipeline by Transition Therapeutics Inc., H1 2014 106 

 Obesity - Pipeline by Suven Life Sciences Ltd., H1 2014 107 

 Obesity - Pipeline by Galapagos NV, H1 2014 108 

 Obesity - Pipeline by Phynova Group Ltd, H1 2014 109 

 Obesity - Pipeline by Orexigen Therapeutics, Inc., H1 2014 110 

 Obesity - Pipeline by DiaMedica Inc., H1 2014 111 

 Obesity - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 112 

 Obesity - Pipeline by Digna Biotech, S.L., H1 2014 113 

 Obesity - Pipeline by Advinus Therapeutics Ltd., H1 2014 114 

 Obesity - Pipeline by Betagenon AB, H1 2014 115 

 Obesity - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 116 

 Obesity - Pipeline by Jenrin Discovery, Inc., H1 2014 117 

 Obesity - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 118 

 Obesity - Pipeline by ObeTherapy Biotechnology, H1 2014 119 

 Obesity - Pipeline by Helsinn Healthcare S.A., H1 2014 120 

 Obesity - Pipeline by Xenon Pharmaceuticals Inc., H1 2014 121 

 Obesity - Pipeline by Spherix Incorporated, H1 2014 122 

 Obesity - Pipeline by Ocera Therapeutics, Inc., H1 2014 123 

 Obesity - Pipeline by AngioChem Inc., H1 2014 124 

 Obesity - Pipeline by Kedem Pharmaceuticals Inc., H1 2014 125 

 Obesity - Pipeline by Zafgen Inc., H1 2014 126 

 Obesity - Pipeline by Ambrx, Inc., H1 2014 127 

 Obesity - Pipeline by Braasch Biotech LLC, H1 2014 128 

 Obesity - Pipeline by Zealand Pharma A/S, H1 2014 129 

 Obesity - Pipeline by Indus Biotech Private Limited, H1 2014 130 

 Obesity - Pipeline by Intarcia Therapeutics, Inc., H1 2014 131 

 Obesity - Pipeline by Thrasos, Inc., H1 2014 132 

 Obesity - Pipeline by Versartis, Inc., H1 2014 133 

 Obesity - Pipeline by Kainos Medicine, Inc., H1 2014 134 

 Obesity - Pipeline by Nordic Bioscience a/s, H1 2014 135 

 Obesity - Pipeline by Avaxia Biologics, Inc., H1 2014 136 

 Obesity - Pipeline by Omeros Corporation, H1 2014 137 

 Obesity - Pipeline by Aegis Therapeutics, LLC, H1 2014 138 

 Obesity - Pipeline by Bridge Bioresearch Plc, H1 2014 139 

 Obesity - Pipeline by Globeimmune, Inc., H1 2014 141 

 Obesity - Pipeline by Targacept, Inc., H1 2014 142 

 Obesity - Pipeline by Molecular Design International, Inc., H1 2014 143 

 Obesity - Pipeline by N-Gene Research Laboratories, Inc., H1 2014 144 

 Obesity - Pipeline by Seek, H1 2014 145 

 Obesity - Pipeline by Vitae Pharmaceuticals, Inc., H1 2014 146 

 Obesity - Pipeline by Galenea Corp., H1 2014 147 

 Obesity - Pipeline by Verva Pharmaceuticals Limited, H1 2014 148 

 Obesity - Pipeline by Regulus Therapeutics Inc., H1 2014 149 

 Obesity - Pipeline by Esperion Therapeutics, Inc., H1 2014 150 

 Obesity - Pipeline by Sorrento Therapeutics, Inc., H1 2014 151 

 Obesity - Pipeline by Domainex Ltd., H1 2014 152 

 Obesity - Pipeline by Alize Pharma SAS, H1 2014 153 

 Obesity - Pipeline by DiscoveryBiomed, Inc., H1 2014 154 

 Obesity - Pipeline by Mitsubishi Pharmaceutical Corporation, H1 2014 155 

 Obesity - Pipeline by Sirona Biochem Corp, H1 2014 156 

 Obesity - Pipeline by Vicore Pharma AB, H1 2014 157 

 Obesity - Pipeline by Carmot Therapeutics, Inc., H1 2014 158 

 Obesity - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 159 

 Obesity - Pipeline by PharmaIN Corporation, H1 2014 160 

 Obesity - Pipeline by Rhythm Pharmaceuticals, H1 2014 161 

 Obesity - Pipeline by Selvita S.A, H1 2014 162 

 Obesity - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 163 

 Obesity - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014 164 

 Obesity - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 165 

 Obesity - Pipeline by X-BODY BioSciences, Inc., H1 2014 166 

 Obesity - Pipeline by Lead Discovery Center GmbH, H1 2014 167 

 Obesity - Pipeline by Adial Pharmaceuticals, LLC, H1 2014 168 

 Obesity - Pipeline by P2D Bioscience, H1 2014 169 

 Obesity - Pipeline by High Point Pharmaceuticals, LLC, H1 2014 170 

 Obesity - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 171 

 Obesity - Pipeline by Chronos Therapeutics Limited, H1 2014 172 

 Obesity - Pipeline by nLife Therapeutics, S.L., H1 2014 173 

 Obesity - Pipeline by XL-protein GmbH, H1 2014 174 

 Obesity - Pipeline by Akron Molecules GmbH, H1 2014 175 

 Assessment by Monotherapy Products, H1 2014 176 

 Assessment by Combination Products, H1 2014 177 

 Number of Products by Stage and Target, H1 2014 180 

 Number of Products by Stage and Mechanism of Action, H1 2014 190 

 Number of Products by Stage and Route of Administration, H1 2014 199 

 Number of Products by Stage and Molecule Type, H1 2014 202 

 Obesity Therapeutics - Recent Pipeline Updates, H1 2014 477 

 Obesity - Dormant Projects, H1 2014 535 

 Obesity - Dormant Projects (Contd..1), H1 2014 536 

 Obesity - Dormant Projects (Contd..2), H1 2014 537 

 Obesity - Dormant Projects (Contd..3), H1 2014 538 

 Obesity - Dormant Projects (Contd..4), H1 2014 539 

 Obesity - Dormant Projects (Contd..5), H1 2014 540 

 Obesity - Dormant Projects (Contd..6), H1 2014 541 

 Obesity - Dormant Projects (Contd..7), H1 2014 542 

 Obesity - Dormant Projects (Contd..8), H1 2014 543 

 Obesity - Dormant Projects (Contd..9), H1 2014 544 

 Obesity - Dormant Projects (Contd..10), H1 2014 545 

 Obesity - Dormant Projects (Contd..11), H1 2014 546 

 Obesity - Discontinued Products, H1 2014 547 

 Obesity - Discontinued Products (Contd..1), H1 2014 548 

 Obesity - Discontinued Products (Contd..2), H1 2014 549 

 Obesity - Discontinued Products (Contd..3), H1 2014 550 

 Obesity - Discontinued Products (Contd..4), H1 2014 551 

 Obesity - Discontinued Products (Contd..5), H1 2014 552 

  

 List of Figures 

 Number of Products under Development for Obesity, H1 2014 35 

 Number of Products under Development for Obesity - Comparative Analysis, H1 2014 36 

 Number of Products under Development by Companies, H1 2014 37 

 Number of Products under Investigation by Universities/Institutes, H1 2014 47 

 Comparative Analysis by Late Stage Development, H1 2014 51 

 Comparative Analysis by Clinical Stage Development, H1 2014 52 

 Comparative Analysis by Early Stage Products, H1 2014 53 

 Assessment by Monotherapy Products, H1 2014 176 

 Assessment by Combination Products, H1 2014 177 

 Number of Products by Top 10 Target, H1 2014 178 

 Number of Products by Stage and Top 10 Target, H1 2014 179 

 Number of Products by Top 10 Mechanism of Action, H1 2014 188 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 189 

 Number of Products by Top 10 Route of Administration, H1 2014 197 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 198 

 Number of Products by Top 10 Molecule Type, H1 2014 200 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 201